Hatch-Waxman and IPR Strategy

Inter partes review (IPR) proceedingshave become an attractive optionfor generic drug manufacturers wishing toutilize the PTAB’s streamlined patent validity decision process while also reaping the benefits of the Hatch-Waxman Act. However, many believe that allowing generics to apply bothof these strategies disrupts the balance between encouraging pharmaceutical innovation andlowering drug prices that the Hatch-Waxman Act intended to preserve. Thisdebate has escalated sincethe Hatch-Waxman Integrity Act of 2018, which seeks to force generics to choose between the Hatch-Waxman framework and IPR.

In this webinar, Principal and Post-Grant Practice Co-Chair Dorothy Whelan and Principal Chad Shear address these complex issues and more, including:

• IPR basics and how they apply to Hatch-Waxman cases
• The “who, when, and where” of IPR filings and the decisions that go into filing
• Recent decisions and arguments impacting Hatch-Waxman and IPR strategy

To access a recording of this webinar or receive a copy of the slides, please contact [email protected].